Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | EDNRA | P25101 | 7/20 | 0.56 |
| ▸ | EDNRB | P24530 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293031 | 0.91 | EDNRB (0.54) | MAPTEDNRAEDNRBALDH1A1PKM | |
| SCHEMBL14701156 | 0.84 | EDNRB (0.54) | MAPTEDNRAEDNRBALDH1A1PKM | |
| SCHEMBL12293606 | 0.78 | MAPT (0.67) | MAPTEDNRAALDH1A1MEN1KMT2A | |
| SCHEMBL12293576 | 0.78 | MAPT (0.67) | MAPTEDNRAEDNRBALDH1A1PKM | |
| SCHEMBL12293583 | 0.78 | MAPT (0.67) | MAPTEDNRAALDH1A1MEN1KMT2A | |
| SCHEMBL12293571 | 0.78 | MAPT (0.67) | MAPTEDNRAEDNRBALDH1A1PKM | |
| SCHEMBL3912876 | 0.77 | KMT2A (0.73) | MAPTEDNRAALDH1A1MEN1KMT2A | |
| SCHEMBL12293577 | 0.77 | MAPT (0.65) | MAPTEDNRAALDH1A1PKMMEN1 | |
| SCHEMBL12293569 | 0.77 | MAPT (0.65) | MAPTEDNRAEDNRBALDH1A1MEN1 | |
| SCHEMBL533130 | 0.76 | PPARG (0.66) | MAPTEDNRAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895608-B2 | Sulfonamide anti-viral compounds | Kineta, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895608-B2 | Sulfonamide anti-viral compounds | Kineta, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8895608-B2 | Sulfonamide anti-viral compounds | Kineta, Inc. (US) | 2014-11-25 | — | — | US | disclosed |
| EP-2560636-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039945-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039945-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130039945-A1 | Anti-Viral Compounds | Kineta, Inc. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2012003030-A9 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012003030-A2 | METHODS OF IDENTIFYING & USING ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2012-01-05 | — | — | WO | disclosed |
| WO-2011133729-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133729-A2 | ANTI-VIRAL COMPOUNDS | Kineta, Inc. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130039887-A1 | Methods of Identifying and Using Anti-Viral Compounds | MAVS, EIF2AK2, DDX5 | MAPT 4165/4885EDNRA 3727/4885EDNRB 3389/4885 |
| US-20130039945-A1 | Anti-Viral Compounds | MAVS, EIF2AK2, IRF3 | MAPT 3520/4885EDNRA 3666/4885EDNRB 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.